sb 203580 has been researched along with mart-1 antigen in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (mart-1 antigen) | Trials (mart-1 antigen) | Recent Studies (post-2010) (mart-1 antigen) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 1,241 | 99 | 446 |
| Protein | Taxonomy | sb 203580 (IC50) | mart-1 antigen (IC50) |
|---|---|---|---|
| HLA class I histocompatibility antigen, A alpha chain | Homo sapiens (human) | 0.2624 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.2624 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.2624 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.2624 | |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | 0.2624 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baghdadi, M; Maekawa, R; Muto, M; Seino, K; Wada, H | 1 |
1 other study(ies) available for sb 203580 and mart-1 antigen
| Article | Year |
|---|---|
Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity.
Topics: Antigen Presentation; Antigens, Neoplasm; CCAAT-Enhancer-Binding Proteins; CD36 Antigens; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Cytotoxicity, Immunologic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Immunotherapy; Lymphocyte Activation; MART-1 Antigen; Myeloid Cells; Neoplasms; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phagocytosis; Pyridines; Receptors, Antigen, T-Cell, gamma-delta; Signal Transduction; T-Lymphocytes; Up-Regulation | 2015 |